Recombinant type VII collagen and its preparation method and application

By expressing type VII collagen in Pichia yeast, the problems of low yield and poor stability of the expression system in the prior art were solved, and efficient and large-scale production was achieved. The obtained recombinant protein has good physical and chemical properties and biological functions. Suitable for a variety of applications.

CN118146354BActive Publication Date: 2024-12-03JIANGSU TRAUTEC MEDICAL TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410248047.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-03-05
Publication Date
2024-12-03
Estimated Expiration
2044-03-05

AI Technical Summary

Technical Problem

In the prior art, the expression system of type VII collagen has low yield and poor stability, making it difficult to achieve large-scale production, and has large molecular weight and poor stability, resulting in limitations in production and application, and commercial production cannot be achieved.

Method used

Using genetic engineering technology, the expression and production of recombinant VII collagen is performed using Pichia eukaryotic expression system. By constructing a recombinant expression vector containing the VII collagen sequence, the host bacteria are electrotransformed and induced, and the secretion and efficient secretion and Purification reduces the difficulty of purification.

Benefits of technology

The expression of type VII collagen was increased, and the obtained recombinant protein has similar physical and chemical properties and biological functions as the original sequence, has a small molecular weight, and has good tissue absorption effect. It is suitable for drugs, medical equipment, and tissue engineering products.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118146354B_ABST
    Figure CN118146354B_ABST
Patent Text Reader

Abstract

The invention provides recombinant type VII collagen and a preparation method and application thereof, and belongs to the fields of biology, genetic engineering and biotechnology. The invention uses genetic engineering technology as a means to increase the expression amount of recombinant type VII collagen, and uses a eukaryotic Pichia pastoris expression system to express and produce recombinant type VII collagen. The recombinant type VII collagen of the invention is expressed in Pichia pastoris, can be efficiently secreted and expressed outside the cell, is not easily degraded during the purification stage, and the difficulty of purification is reduced. The recombinant type VII collagen has similar physical and chemical properties and biological functions to the original sequence, has a small molecular weight, has a good effect on tissue absorption, can be made into a composition containing collagen, and has good applications in the fields of drugs, drug compositions, medical devices, biomaterials, tissue engineering products, cosmetics or health products.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the fields of biology, genetic engineering and biotechnology, and specifically relates to recombinant type VII collagen and a preparation method and application thereof. Background Art

[0002] Anchoring fibers are attachment structures that mediate the adhesion of the true epidermis of human skin, among which type VII collagen (Col7) is the main component of anchoring fibers (AFs). Type VII collagen connects the basal layer to the underlying tissue by interacting with other types of collagen and part of the extracellular matrix. Col7 is a homotrimer, that is, composed of three α chains. The Col7 gene encodes an α chain of 290 kDa, and the three α chains form a 900 kDa homotrimer. In the Col7, each α chain has a 145 kDa central collagen triple helix with a fragment sequence characterized by repeated Gly-XY amino acids. The central domain of the helix is ​​flanked by a larger 145 kDa non-collagenous domain (NC1) amino terminal and a 34 kDa carboxyl terminal non-collagenous domain (NC2). In the dermis, Col7 molecules form disulfide-bonded tail-to-tail antiparallel dimers through the carboxyl-terminal NC2, and the NC2 domain and its adjacent triple helical domain initiate the triple helical assembly of type VII collagen; then part of the NC2 domain is removed by proteolysis, and the antiparallel dimers aggregate laterally to form anchoring fibers, which interact with microfibrils, collagen fibers, and microthread-like fibers in the dermis. These interactions are believed to anchor the epidermis and its underlying basement membrane zone to the underlying dermis.

[0003] Studies have shown that NC1 interacts with multiple extracellular matrix (ECM) components, including fibronectin, laminin 5, collagen type I, and collagen IV. Structural changes in type VII collagen may lead to functional disruption of its interaction with ECM components, resulting in separation of the epidermis from the dermis, leading to dystrophic epidermolysis bullosa (DEB); Col7 mutations lead to a human skin fragility disease, recessive dystrophic epidermolysis bullosa (RDEB), which results in persistent wound nonhealing. Therefore, Col7 is required for the organization of laminin 332 re-epithelialization at the dermal-epidermal junction, and its absence will disrupt the organization of laminin 332 during wound healing, thereby disrupting the strictly polarized expression of integrin α6β4 in basal keratinocytes and negatively affecting laminin 332 / integrin.

[0004] Studies have shown that Col7 promotes skin wound healing through two interrelated mechanisms. First, Col7 enables re-epithelialization through the organization of laminin-332 at the dermal-epidermal junction. During wound healing, the loss of Col7 disrupts the organization of laminin-332, which in turn disrupts the strictly polarized expression of integrin α6β4 in basal keratinocytes and negatively affects the laminin-332 / integrin α6β4 signaling axis that directs keratinocyte migration. Col7 then supports dermal fibroblast migration and regulates their cytokine production in granulation tissue. Therefore, Col7 has a key role in physiological wound healing in humans and mice, which may help develop therapeutic strategies for RDEB as well as other chronic wounds.

[0005] VII collagen is a macromolecule with a molecular weight of more than 300,000 Daltons. The synthesis and separation of collagen macromolecules are costly and difficult. In terms of stability, macromolecular collagen is easily degraded and has poor stability. It is very easy to cause protein loss and operational complexity during the production and separation process. There are also limitations in application, and large-scale production cannot be achieved. In addition, there are not many expression systems for type VII collagen at present, which are mainly divided into mammalian cells and Escherichia coli. The cost of mammalian cell culture is high, the growth cycle is slow, and the expression level is 15-20 mg / L. The expression level is low. Although it is secreted into the supernatant, there are many purification steps and product losses, which cannot be industrialized. Although the yield of the Escherichia coli expression system is higher than that of mammalian cells, it has not reached the scale of commercial production. Therefore, the expression yield of the above two expression systems is low, the protein stability is poor and easy to degrade, and it is limited to the scale of laboratory research. In order to realize the commercialization of type VII collagen products, it is necessary to provide a recombinant type VII collagen with high expression level and its expression system and construction method. Summary of the invention

[0006] In view of some deficiencies in the prior art, the present invention provides a recombinant type VII collagen protein and a preparation method and application thereof; the present invention uses genetic engineering technology as a means to increase the expression amount of recombinant type VII collagen protein, and uses a eukaryotic Pichia pastoris expression system to express and produce recombinant type VII collagen protein; the recombinant type VII collagen protein of the present invention is expressed in Pichia pastoris, can be efficiently secreted and expressed outside the cell, is not easily degraded during the purification stage, and reduces the difficulty of purification; the recombinant type VII collagen protein has similar physical and chemical properties and biological functions to the original sequence, has a small molecular weight, has a better effect on tissue absorption, can be made into a composition containing collagen protein, and has good applications in the fields of drugs, drug compositions, medical devices, biomaterials, tissue engineering products, cosmetics or health products.

[0007] The present invention achieves the above technical objectives through the following technical means.

[0008] The present invention first provides a type VII collagen, which includes an amino acid sequence as shown in SEQ ID No.1, SEQ ID No.3, SEQ ID No.5, SEQ ID No.7, SEQ ID No.9 or SEQ ID No.11, or an amino acid sequence that is more than 80%, more than 85%, more than 90%, more than 95%, more than 96%, more than 97%, more than 98%, or more than 99% identical to SEQ ID No.1, SEQ ID No.3, SEQ ID No.5, SEQ ID No.7, SEQ ID No.9 or SEQ ID No.11, and maintains the biological activity of the collagen.

[0009] The present invention also provides a nucleic acid encoding the above-mentioned type VII collagen.

[0010] The present invention also provides a recombinant vector, the recombinant vector comprising the above nucleic acid. Preferably, the recombinant vector includes but is not limited to pPICZαB, pFLDα, pPIC9K, and the connection site is between XhoI and NotI.

[0011] The present invention also provides a method for preparing the above-mentioned type VII collagen, characterized in that the method comprises:

[0012] (1) selecting a type VII collagen sequence to construct a collagen tandem sequence, and then constructing a recombinant expression vector comprising the collagen tandem sequence;

[0013] (2) linearizing the obtained recombinant expression vector with Sal I to obtain a linearized plasmid;

[0014] (3) electroporating the linearized plasmid into a host bacterium, screening and verifying to obtain a recombinant engineered bacterium containing or expressing type VII collagen, and inducing expression by fermentation to obtain the type VII collagen.

[0015] Preferably, the collagen tandem sequence is expressed in tandem repetitions with type VII collagen as the basic unit, and there is a site for Kex2 enzyme recognition and cleavage between every two adjacent basic units in the collagen tandem sequence.

[0016] Preferably, the type VII collagen comprises an amino acid sequence as shown in SEQ ID No.1, SEQ ID No.3, SEQ ID No.5, SEQ ID No.7, SEQ ID No.9 or SEQ ID No.11, or an amino acid sequence that is more than 80%, more than 85%, more than 90%, more than 95%, more than 96%, more than 97%, more than 98%, or more than 99% identical to SEQ ID No.1, SEQ ID No.3, SEQ ID No.5, SEQ ID No.7, SEQ ID No.9 or SEQ ID No.11, and maintains the biological activity of the collagen.

[0017] Preferably, the collagen tandem sequence may further include a recognition and cleavage site for the Ste13 enzyme between each two adjacent basic units.

[0018] Preferably, the recognition site of the Kex2 enzyme includes a KR or RR dibasic amino acid residue, followed by EA, EAEA or other amino acid residues that facilitate cleavage by the Kex2 enzyme or the Ste 13 enzyme.

[0019] Preferably, the amino acids of the collagen tandem sequence include a sequence as shown in SEQ ID No.2, SEQ ID No.4, SEQ ID No.6, SEQ ID No.8, SEQ ID No.10 or SEQ ID No.12, or an amino acid sequence having more than 80%, more than 85%, more than 90%, more than 95%, more than 96%, more than 97%, more than 98%, or more than 99% identity with the above.

[0020] Preferably, the nucleic acid encoding the collagen tandem sequence includes the nucleotide sequence shown in SEQ ID No. 13 to SEQ ID No. 18, or a degenerate sequence thereof.

[0021] Preferably, in step (1), the recombinant expression vector includes but is not limited to pPICZαB, pFLDα, pPIC9K, and the connection site is between XhoI and NotI.

[0022] Preferably, in step (3), the host bacteria include Pichia pastoris, Saccharomyces cerevisiae, Hansenula, etc., preferably Pichia pastoris.

[0023] Preferably, in step (3), the recombinant engineered bacteria are deposited in the General Microbiology Center of China National Microbiological Culture Collection Administration, with the deposit numbers being: CGMCC No.29601, CGMCC No.29602, CGMCC No.29603, CGMCC No.29604, CGMCC No.29605, CGMCC No.29606.

[0024] The present invention also provides type VII collagen prepared according to the above method.

[0025] The present invention also provides a composition, which comprises the type VII collagen, or the type VII collagen encoded by the nucleic acid, or the recombinant vector, or the type VII collagen obtained by the method; the composition includes drugs, medical devices, biomaterials, tissue engineering products, cosmetics or health products.

[0026] The present invention also provides a product, which comprises the type VII collagen, the type VII collagen encoded by the nucleic acid, the recombinant vector, the type VII collagen obtained by the method, or the composition; the product includes drugs, medical devices, biomaterials, tissue engineering products, cosmetics or health products.

[0027] The present invention also provides the use of the type VII collagen, or the type VII collagen encoded by the nucleic acid, or the recombinant vector, or the type VII collagen obtained by the method, or the composition, or the product in the preparation of drugs, medical devices, biomaterials, tissue engineering products, cosmetics or health products.

[0028] Compared with the prior art, the present invention has the following beneficial effects:

[0029] (1) In the type VII collagen monomer described in the present invention, SEQ ID No.1 contains M and H, and has antioxidant activity. SEQ ID No.3, SEQ ID No.5, and SEQ ID No.7 contain RGD, which can specifically bind to 11 integrins and effectively promote cell adhesion to biomaterials. SEQ ID No.9 contains charged amino acids, which can ionize charges and has a high isoelectric point. The six groups of sequences obtained by the series connection of the above six groups of type VII collagen monomers are all GXY triplets. The six groups of recombinant collagen sequences involved are all expressed in Pichia pastoris, can be efficiently secreted and expressed outside the cell, are not easily degraded during the purification stage, and the difficulty of purification is reduced.

[0030] (2) The sequence of the collagen protein described in the present invention is derived from human type VII collagen (Q02388·CO7A1_HUMAN), and the sequence is derived from the triple helix region: a sequence of about 50 amino acids is selected, KR is added to the C-terminus, EA is added to the N-terminus, and 6 copies are connected in series to make the target sequence size about 40KD to adapt to the optimal expression range of Pichia pastoris. After expression in Pichia pastoris, kex2 contained in Pichia pastoris itself cuts the KR carboxyl terminus, ste13 cuts the nitrogen-terminal EA, and Kex1 cuts the remaining KR residues, and secretes them into the extracellular space through the secretory signal peptide.

[0031] The technical solution of the present invention greatly improves the yield of type VII collagen expression; the technical solution of the present invention does not introduce exogenous proteins and does not use any in vitro enzyme cleavage method. During the process of intracellular secretion of type VII collagen, the residual amino acid residues at the enzyme cleavage site during the repeated tandem design will be removed to obtain type VII collagen without non-collagen sequences or with 100% homology to the corresponding region of natural collagen; the entire expression system avoids the cost and risk of exogenous protein residues caused by the use of protease cleavage in vitro, and can also shorten the time and cost of the subsequent purification process.

[0032] (3) The recombinant type VII collagen obtained by the method of the present invention has similar physical and chemical properties and biological functions to the original sequence, has a smaller molecular weight, and has a better effect on tissue absorption. The present invention uses NIH / 3T3 cells cultured in vitro to conduct cell adhesion experiments with type VII collagen and commercial collagen. The experiment shows that there is no significant difference in the adhesion activity of the recombinant type VII collagen of the present invention and commercial type I collagen. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Figure 1 This is an agarose gel verification picture of the recombinant engineering strain.

[0034] Figure 2 This is the supernatant of recombinant collagen expression in shake flasks after 48h and 72h of induction.

[0035] Figure 3 This is the result of protein spectrum detection of recombinant collagen.

[0036] Figure 4 Mass spectrometry analysis results

[0037] Figure 5 The electrophoresis diagram of the supernatant of each recombinant collagen 5L tank fermentation

[0038] Figure 6 The electrophoresis diagram of recombinant collagen after purification

[0039] Figure 7 This is a graph showing the results of cell adhesion activity detection.

[0040] Figure 8 This is the result of cell migration area ratio detection.

[0041] Fig. 9 This is a picture of cell migration. DETAILED DESCRIPTION

[0042] In order to enable those skilled in the art to better understand the technical solution of the present invention, the preferred embodiments of the present invention are described in detail below, but the following embodiments do not limit the protection scope of the present invention.

[0043] In the embodiments of the present invention, those that are not described in detail are all completed by conventional experimental methods. Those processes involved in the embodiments that are not described in detail are all understandable and easily implementable by those skilled in the art based on the product instructions or basic knowledge in the field, and therefore are not described in detail.

[0044] Embodiment 1:

[0045] S1. Design of amino acid sequence:

[0046] A sequence of about 50 amino acids from the triple helix region of human type VII collagen (Q02388·CO7A1_HUMAN) was selected, KR was added to the C-terminus, EA was added to the N-terminus, and 6 copies were connected in series to make the target sequence size about 40KD to adapt to the optimal expression range of Pichia pastoris. After expression in Pichia pastoris, kex2 contained in Pichia pastoris itself cuts at the carboxyl terminus of KR, ste13 cuts the nitrogen-terminal EA, and Kex1 cuts the remaining KR residues, which are secreted into the extracellular space through the secretory signal peptide.

[0047] (1) 2156-2207AA of Q02388.CO7A1-HUMAN was selected, LE was added to the C-terminus, and the obtained sequence was named 705. The sequence was shown in SEQ ID No. 1. On the basis of SEQ ID No. 1, EA was added to the N-terminus and KR was added to the C-terminus to form a monomer. The monomer was repeated 6 times to form the amino acid sequence shown in SEQ ID No. 2, thus obtaining the recombinant type VII collagen tandem sequence.

[0048] SEQ ID No.1:

[0049] GERGMAGPEGKPGLQGPRGPPGPVGGHGDPGPPGAPGLAGPAGPQGPSGLKGLE;

[0050] SEQ ID No.2:

[0051] KREAGERGMAGPEGKPGLQGPRGPPGPVGGHGDPGPPGAPGLAGPAGPQGPSGLKGLEKREAGERGMAGPEGKPGLQGPRGPPGPVGGHGDPGPPGAPGLAGPAGPQGPSGLKGLEKREAGERGMAGPEGKPGLQGPRGPPGPVGGHGDPGPPGAPGLAGPAGPQGPSGLKGLEK REAGERGMAGPEGKPGLQGPRGPPGPVGGHGDPGPPGAPGLAGPAGPQGPSGLKGLEKREAGERGMAGPEGKPGLQGPRGPPGPVGGHGDPGPPGAPGLAGPAGPQGPSGLKGLEKREAGERGMAGPEGKPGLQGPRGPPGPVGGHGDPGPPGAPGLAGPAGPQGPSGLKGLEKR.

[0052] (2) 2527-2568AA of Q02388.CO7A1-HUMAN was selected, LE was added to the C-terminus, and the obtained sequence was named 706, and the sequence was shown in SEQ ID No. 3. The SEQ ID No. 3 contains an RGD motif, can specifically bind to 11 integrins, can effectively promote cell adhesion to biomaterials, and contains a large amount of ionizable polar amino acids.

[0053] Based on SEQ ID No. 3, EA was added to the N-terminus and KR was added to the C-terminus to form a monomer, and this was repeated 6 times to form an amino acid sequence as shown in SEQ ID No. 4, thereby obtaining recombinant type VII collagen.

[0054] SEQ ID No.3: GPPGPRGAKGDMGERGPRGLDGDKGPRGDNGDPGDKGSKGEPGLE; SEQ ID No.4:

[0055] KREAGPPGPRGAKGDMGERGPRGLDGDKGPRGDNGDPGDKGSKGEPGLEKREAGPPGPRGAKGDMGERGPRGLDGDKGPRGDNGDPGDKGSKGEPGLEKREAGPPGPRGAKGDMGERGPRGLDGDKGPRGDNGDPGDKGSKGEPGLEK REAGPPGPRGAKGDMGERGPRGLDGDKGPRGDNGDPGDKGSKGEPGLEKREAGPPGPRGAKGDMGERGPRGLDGDKGPRGDNGDPGDKGSKGEPGLEKREAGPPGPRGAKGDMGERGPRGLDGDKGPRGDNGDPGDKGSKGEPGLEKR.

[0056] (3) 1988-2020AA of Q02388.CO7A1-HUMAN was taken and named as 707, and the sequence was shown in SEQ ID No. 5. The SEQ ID No. 5 contained an RGD motif, could specifically bind to 11 integrins, could effectively promote cell adhesion to biomaterials, and contained a large amount of ionizable polar amino acids.

[0057] Based on SEQ ID No. 5, EA was added to the N-terminus and KR was added to the C-terminus to form a monomer, and this was repeated 6 times to form an amino acid sequence as shown in SEQ ID No. 6, thereby obtaining recombinant type VII collagen.

[0058] SEQ ID No.5:GPPGKEGPIGFPGERGLKGDRGDPGPQGPPGLA;

[0059] SEQ ID No.6:

[0060] KREAGPPGKEGPIGFPGERGLKGDRGDPGPQGPPGLAKREAGPPGKEGPIGFPGERGLKGDRGDPGPQGPPGLAKREAGPPGKEGPIGFPGERGLKGDRGDPGPQGPPGLAKREAGPPGKEGPIGFPGERGLKGDRGDPGPQGPPGLAKREAGPPGKEGPIGFPGERGLKGDRGDPGPQGPPGLAKREAGPPGKEGPIGFPGERGLKGDRGDPGPQGPPGLAKR.

[0061] (4) 1314-1352AA of Q02388.CO7A1-HUMAN was selected, LE was added to the C-terminus, and the obtained sequence was named 708, and the sequence was shown as SEQ ID No. 7. The SEQ ID No. 7 contains an RGD motif, can specifically bind to 11 integrins, can effectively promote cell adhesion to biomaterials, and contains a large amount of ionizable polar amino acids.

[0062] Based on SEQ ID No. 7, EA was added to the N-terminus and KR was added to the C-terminus to form a monomer, and this was repeated 6 times to form an amino acid sequence as shown in SEQ ID No. 8, thereby obtaining recombinant type VII collagen.

[0063] SEQ ID No.7:GNPGTPGAPGLKGSPGLPGPRGDPGERGPRGPKGEPGAPGLE;

[0064] SEQ ID No.8:

[0065] KREAGNPGTPGAPGLKGSPGLPGPRGDPGERGPRGPKGEPGAPGLEKREAGNPGTPGAPGLKGSPGLPGPRGDPGERGPRGPKGEPGAPGLEKREAGNPGTPGAPGLKGSPGLPGPRGDPGERGPRGPKGEPGAPGLEK REAGNPGTPGAPGLKGSPGLPGPRGDPGERGPRGPKGEPGAPGLEKREAGNPGTPGAPGLKGSPGLPGPRGDPGERGPRGPKGEPGAPGLEKREAGNPGTPGAPGLKGSPGLPGPRGDPGERGPRGPKGEPGAPGLEKR.

[0066] (5) 2617-2655AA of Q02388.CO7A1-HUMAN was selected and the obtained sequence was named 709, and the sequence was shown in SEQ ID No. 9. Based on SEQ ID No. 9, EA was added to the N-terminus and KR was added to the C-terminus to form a monomer, which was repeated 6 times to form the amino acid sequence shown in SEQ ID No. 10, thereby obtaining recombinant type VII collagen.

[0067] SEQ ID No.9:GFMGPRGLKGERGVKGACGLDGEKGDKGEAGPPGRPGLA;

[0068] SEQ ID No.10:

[0069] KREAGFMGPRGLKGERGVKGACGLDGEKGDKGEAGPPGRPGLAKREAGFMGPRGLKGERGVKGACGLDGEKGDKGEAGPPGRPGLAKREAGFMGPRGLKGERGVKGACGLDGEKGDKGEAGPPGRPGLAK REAGFMGPRGLKGERGVKGACGLDGEKGDKGEAGPPGRPGLAKREAGFMGPRGLKGERGVKGACGLDGEKGDKGEAGPPGRPGLAKREAGFMGPRGLKGERGVKGACGLDGEKGDKGEAGPPGRPGLAKR

[0070] (6) 1483-1527AA of Q02388.CO7A1-HUMAN was selected, LE was added to the C-terminus, and the obtained sequence was named 710, and the sequence was shown in SEQ ID No. 11. Based on SEQ ID No. 11, EA was added to the N-terminus and KR was added to the C-terminus to form a monomer, and the result was repeated 6 times to form the amino acid sequence shown in SEQ ID No. 12, thereby obtaining recombinant type VII collagen.

[0071] SEQ ID No.11:

[0072] GFPGPLGEAGEKGERGPPGPAGSRGLPGVAGRPGAKGPEGPPGPTGLE;

[0073] SEQ ID No.12:

[0074] KREAGFPGPLGEAGEKGERGPPGPAGSRGLPGVAGRPGAKGPEGPPGPTGLEKREAGFPGPLGEAGEKGERGPPGPAGSRGLPGVAGRPGAKGPEGPPGPTGLEKREAGFPGPLGEAGEKGERGPPGPAGSRGLPGVAGRPGAKGPEGPPGPTGLEK REAGFPGPLGEAGEKGERGPPGPAGSRGLPGVAGRPGAKGPEGPPGPTGLEKREAGFPGPLGEAGEKGERGPPGPAGSRGLPGVAGRPGAKGPEGPPGPTGLEKREAGFPGPLGEAGEKGERGPPGPAGSRGLPGVAGRPGAKGPEGPPGPTGLEKR.

[0075] S2. Synthesis of DNA sequences and construction of recombinant expression vectors:

[0076] Nanjing GenScript Biotech Co., Ltd. was commissioned to synthesize nucleic acid sequences encoding the above-mentioned amino acid sequences SEQ ID No.2, SEQ ID No.4, SEQ ID No.6, SEQ ID No.8, SEQ ID No.10, and SEQ ID No.12, and the corresponding nucleic acid sequences are shown in SEQ ID No.13 to SEQ ID No.18, respectively.

[0077] The synthesized gene fragments were cloned into pPICZαB respectively, and the exogenous target protein sequences were cloned using XhoI and NotI as restriction sites, so that the target fragments were accurately inserted into the secretory vector reading frame containing the secretion signal α-factor, and recombinant expression vectors expressing SEQ ID No.2, SEQ ID No.4, SEQ ID No.6, SEQ ID No.8, SEQ ID No.10, and SEQ ID No.12 were obtained and named pPICZαB-705 to pPICZαB-710.

[0078] SEQ ID No.13 to SEQ ID No.18 are shown below, wherein "CTCGAG" is an XhoⅠ restriction site and "GCGGCCGC" is a NotⅠ restriction site.

[0079] SEQ ID No.13:

[0080]

[0081] SEQ ID No.14:

[0082] CTCGAGAAACGCGAGGCAGGCCCGCCTGGACCCCGAGGTGCCAAGGGGGATATGGGGGAGCGTGGGCCCAGAGGTCTTGACGGCGATAAAGGGCCCCGAGGTGATAATGGTGACCCTGGTGATAAAGGGAGCAAAGGCGAACCCGGTTTAGAGAAACGAGAAGCGGGCCCTCCTGGCCCTCGTGGCGCTAAAGGGGACATGGGTGAGCGCGGCCCACGGGGCCTCGACGGTGATAAGGGGCCTCGTGGTGATAACGGCGACCCCGGCGACAAGGGTTCTAAAGGCGAACCGGGACTAGAGAAACGAGAGGCAGGGCCACCAGGGCCTAGAGGCGCCAAAGGCGACATGGGGGAAAGGGGTCCGCGGGGCTTGGACGGGGACAAGGGACCACGTGGTGACAACGGAGATCCAGGAGATAAAGGGTCTAAGGGGGAACCCGGATTAGAGAAACGTGAGGCAGGCCCACCGGGGCCCCGCGGTGCTAAGGGAGATATGGGCGAGAGGGGCCCACGCGGTCTGGACGGAGATAAAGGCCCAAGAGGGGACAATGGTGATCCTGGAGATAAAGGTAGTAAGGGAGAACCAGGCCTAGAGAAGAGGGAGGCGGGTCCCCCTGGGCCGCGGGGGGCGAAAGGCGATATGGGGGAACGCGGACCTCGTGGATTGGACGGCGATAAGGGTCCCAGGGGAGATAACGGTGACCCGGGGGATAAAGGATCGAAGGGCGAACCGGGACTGGAAAAGCGGGAAGCCGGTCCTCCGGGTCCTCGGGGTGCTAAGGGAGACATGGGGGAAAGAGGGCCGAGAGGACTTGATGGAGATAAGGGACCGCGCGGTGATAATGGCGACCCGGGGGACAAAGGTTCAAAGGGTGAACCAGGATTAGAAAAAAGGTGAGCGGCCGC。

[0083] SEQ ID No.15:

[0084] CTCGAGAAAAGAGAGGCGGGACCGCCTGGTAAAGAAGGACCGATTGGGTTCCCTGGAGAACGGGGGCTGAAGGGTGATCGCGGCGACCCTGGACCCCAAGGGCCCCCGGGTTTGGCGAAGCGCGAGGCTGGGCCTCCAGGCAAGGAAGGTCCCATCGGGTTCCCTGGAGAGAGGGGTCTAAAAGGCGATAGAGGCGATCCCGGACCACAGGGTCCTCCGGGGCTGGCAAAGCGCGAGGCAGGACCACCGGGTAAAGAAGGTCCGATCGGATTTCCTGGGGAGAGAGGTCTTAAGGGGGATCGAGGTGATCCTGGGCCTCAGGGCCCACCGGGCCTTGCCAAAAGGGAGGCCGGTCCACCCGGAAAGGAGGGCCCCATTGGATTCCCGGGCGAACGGGGTTTAAAGGGAGATCGTGGCGATCCCGGACCGCAGGGTCCGCCCGGCCTCGCTAAGCGTGAAGCGGGGCCCCCAGGGAAGGAGGGCCCAATAGGTTTTCCCGGGGAACGAGGATTAAAAGGTGACCGGGGGGACCCAGGGCCACAAGGACCGCCTGGCCTCGCCAAACGAGAAGCAGGCCCACCCGGGAAAGAAGGTCCGATAGGCTTTCCCGGTGAGCGAGGGTTGAAGGGAGACAGGGGCGACCCAGGCCCTCAAGGCCCTCCTGGTCTAGCTAAACGTTGAGCGGCCGC。

[0085] SEQ ID No.16:

[0086] CTCGAGAAGCGTGAGGCAGGTAATCCCGGCACACCAGGGGCGCCAGGATTGAAAGGGTCCCCGGGACTGCCGGGACCACGGGGCGACCCGGGCGAACGCGGACCTCGGGGCCCCAAGGGAGAGCCAGGGGCGCCTGGATTGGAGAAACGGGAAGCAGGAAACCCGGGTACTCCGGGGGCACCCGGTCTTAAAGGCAGCCCCGGACTTCCTGGACCCCGGGGCGATCCTGGGGAGCGAGGCCCGAGGGGTCCGAAGGGCGAACCGGGTGCTCCTGGGCTCGAAAAACGGGAGGCCGGGAATCCAGGCACCCCCGGGGCTCCTGGGTTAAAAGGGTCGCCTGGGCTACCCGGTCCCCGCGGTGACCCTGGAGAGAGGGGGCCACGAGGGCCTAAGGGCGAACCAGGGGCGCCAGGATTAGAAAAAAGAGAGGCGGGTAACCCAGGTACCCCCGGTGCCCCGGGACTTAAGGGCTCTCCCGGGCTGCCAGGTCCTCGCGGTGACCCTGGAGAAAGAGGTCCTCGTGGACCGAAGGGGGAACCTGGGGCTCCTGGTTTAGAAAAGCGTGAGGCCGGCAACCCAGGGACGCCAGGAGCCCCCGGACTGAAAGGCTCACCCGGCCTACCAGGCCCGAGGGGTGATCCTGGTGAGCGAGGTCCCAGGGGTCCGAAGGGTGAACCTGGCGCCCCCGGATTGGAGAAAAGAGAGGCTGGTAATCCAGGTACTCCAGGGGCACCGGGTTTAAAAGGGAGTCCAGGACTACCGGGACCACGAGGTGATCCTGGCGAACGCGGCCCGCGTGGCCCCAAGGGAGAACCGGGCGCTCCCGGATTAGAAAAAAGATGAGCGGCCGC。

[0087] SEQ ID No.17:

[0088] CTCGAGAAACGGGAGGCTGGCTTCATGGGTCCGCGCGGTTTAAAAGGCGAAAGAGGAGTGAAGGGAGCCTGCGGTCTGGACGGAGAAAAAGGTGATAAGGGCGAAGCGGGACCACCTGGCAGGCCAGGACTAGCTAAGCGTGAAGCGGGTTTCATGGGGCCCCGGGGATTAAAGGGAGAACGGGGAGTCAAAGGCGCATGTGGGCTTGATGGGGAGAAAGGGGACAAAGGGGAGGCAGGCCCGCCAGGCCGTCCAGGCCTAGCGAAACGCGAAGCTGGTTTTATGGGGCCTCGTGGCCTCAAAGGGGAAAGGGGCGTTAAGGGAGCCTGTGGTTTGGATGGCGAAAAAGGAGACAAGGGAGAAGCAGGGCCTCCAGGGCGACCGGGTTTAGCTAAGCGCGAAGCCGGTTTTATGGGACCCCGAGGCCTAAAGGGGGAGAGAGGTGTAAAGGGAGCTTGCGGATTAGATGGGGAGAAGGGTGATAAAGGCGAGGCGGGACCCCCGGGCAGGCCCGGGTTGGCAAAGAGAGAGGCTGGGTTCATGGGCCCTCGTGGTTTGAAAGGCGAGCGCGGTGTCAAAGGTGCATGCGGCTTAGACGGTGAGAAGGGTGACAAGGGAGAAGCTGGGCCGCCTGGTCGGCCGGGCCTGGCCAAACGAGAAGCAGGATTTATGGGTCCACGCGGGCTGAAAGGCGAGAGAGGTGTGAAAGGGGCGTGTGGTCTTGATGGGGAGAAGGGCGACAAGGGGGAGGCCGGACCTCCCGGACGTCCCGGACTTGCCAAAAGGTGAGCGGCCGC。

[0089] SEQ ID No.18:

[0090] CTCGAGAAAAGAGAAGCGGGCTTCCCCGGACCCCTAGGGGAAGCTGGGGAGAAGGGAGAACGGGGACCGCCGGGACCCGCTGGTTCTCGCGGGCTTCCGGGGGTGGCAGGCCGCCCCGGAGCAAAGGGCCCCGAGGGTCCGCCCGGACCAACTGGCCTAGAAAAACGAGAAGCCGGATTTCCTGGGCCTTTGGGTGAAGCCGGTGAAAAAGGCGAAAGGGGGCCACCCGGACCCGCCGGTTCACGAGGACTCCCTGGCGTTGCGGGCAGACCAGGAGCAAAGGGCCCGGAAGGTCCCCCAGGTCCTACAGGTCTGGAGAAACGTGAGGCTGGCTTTCCGGGTCCGTTAGGCGAGGCCGGAGAAAAGGGGGAACGAGGTCCGCCGGGACCAGCGGGGTCCAGAGGTTTACCTGGGGTAGCGGGGAGGCCTGGCGCCAAGGGTCCTGAGGGCCCTCCAGGGCCAACTGGTTTAGAAAAACGAGAGGCTGGCTTCCCCGGACCCTTAGGAGAAGCAGGCGAGAAAGGGGAACGCGGACCTCCAGGCCCCGCAGGGTCGCGTGGCCTTCCTGGCGTAGCAGGTAGACCGGGAGCAAAAGGCCCGGAAGGGCCACCAGGGCCTACCGGCTTGGAAAAGCGGGAGGCTGGTTTTCCTGGACCGCTCGGAGAAGCCGGCGAGAAGGGGGAGAGAGGACCTCCCGGGCCAGCTGGTAGTCGCGGGCTTCCAGGTGTGGCGGGGCGGCCCGGGGCGAAGGGCCCGGAGGGGCCACCTGGTCCAACGGGATTGGAGAAACGTGAAGCGGGCTTCCCCGGACCTCTGGGCGAGGCTGGTGAGAAAGGAGAAAGGGGTCCTCCAGGTCCGGCCGGTAGCCGGGGACTACCGGGGGTCGCTGGTAGGCCTGGTGCAAAAGGACCCGAGGGGCCCCCAGGGCCGACGGGCCTGGAGAAGCGTTGAGCGGCCGC。

[0091] S3. Construction of recombinant engineering strains and screening of strains:

[0092] 10 μg of the recombinant expression vectors with different sequences obtained in step 2 were linearized with Sal I (Dalian TaKaRa) enzyme, digested in a metal bath at 37°C for 30 min, purified with a PCR product purification kit (Shanghai Biotechnology, according to the kit instructions), and the linearized plasmids were recovered.

[0093] The linearized plasmid was electroporated into the competent cells of the host strain Pichia pastoris X33 (purchased from Thermo Fisher Scientific), and then 200 μL of the electroporated bacterial solution was spread on a YPDZ (100 μg / mL) plate and cultured in an inverted incubator at 30°C for 2-3 days until a single colony (positive transformant) appeared.

[0094] Use a sterilized pipette tip to pick up a single colony and streak it on a YPDZ (300μg / mL) plate, and invert it in a 30℃ biochemical incubator for 2-3 days until a single colony (positive transformant) appears. Pick 16 single colonies for each sequence in 200mL YPD medium, place them in a 96-well plate, and incubate them in a 30℃ biochemical incubator for 2 days. Take 50μL of the bacterial solution to extract the template, take 2μL of the extracted template and add it to the PCR tube, perform polymerase chain reaction by PCR, and verify the target band by nucleic acid electrophoresis after the reaction.

[0095] The primers in the above PCR reaction process are:

[0096] 5'AOX:GACTGGTTCCAATTGACAAGC (SEQ ID No. 19);

[0097] 3'AOX:GCAAATGGCATTCTGACATCC (SEQ ID No. 20);

[0098] The conditions of PCR reaction were as follows: 94°C for 5 min; 94°C for 30 s, 55°C for 30 s, and 72°C for 2 min for 30 cycles.

[0099] The results of nucleic acid electrophoresis verification are as follows Figure 1 As shown, from Figure 1 It can be seen that the target band is about 1200bp-1500bp. Compared with the marker size band, the one around 1200bp-1500bp is the positive bacteria. The selected positive strain contains the nucleic acid sequence expressing the target protein. The positive strain is selected for subsequent strain screening experiments.

[0100] The positive strains are inoculated on a plate containing high concentrations of Zeocin. The number of positive strains growing on the plate containing high concentrations of Zeocin is used to determine whether the strain contains multiple copies of the target gene. If the positive strain can grow on the plate containing high concentrations of Zeocin, it means that the strain contains multiple copies of the target gene, that is, multiple recombinant fragments have entered the yeast and integrated into the chromosome of the yeast through homologous recombination. Through screening, high-copy, highly efficient recombinant engineered bacteria can be obtained.

[0101] The obtained high-copy, high-efficiency expression recombinant engineered bacteria were sent to the General Microbiology Center of China Culture Collection Administration for Microorganisms for preservation, with the address at No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing. The preservation numbers are: CGMCC No. 29601, CGMCC No. 29602, CGMCC No. 29603, CGMCC No. 29604, CGMCC No. 29605, and CGMCC No. 29606. The preservation dates are all January 12, 2024, and the classification name is: Komagataella phaffii.

[0102] S4. Induced expression and identification of recombinant collagen:

[0103] Select the strain with the target band and inoculate it into 15 mL of BMGY medium, and culture it at 28-30°C and 220 rpm until the OD600 is 2-15 (16-24 h). Centrifuge at 1500-3000g for 5 min at room temperature, collect the cells, and resuspend them in BMMY medium to a value of OD600 of 2-15. 600 The cell culture medium was kept at 28-30℃ and 220rpm for 3 days. Methanol was added at 1% final volume every 12 hours. Samples were taken after 48 hours and 72 hours of induction. The supernatant was collected by centrifugation at 1500-3000g for 5 minutes at room temperature. 2× loading buffer (Coomassie brilliant blue, denaturant DTT, SDS buffer) was added to the collected expression supernatant, heated in a 100℃ metal bath for 5 minutes, and GLASSgel precast gel Tricine protein gel detection was performed. The test results were as follows: Figure 2 As shown in the figure, it can be seen that each target band can be secreted into the culture supernatant.

[0104] The expected target bands of 705, 706, 707, 708, 709 and 710 on the GLASS gel Tricine were cut out and digested with trypsin. The peptides of the recombinant collagen after trypsin digestion were detected by Nano-HPLC-MS / MS mass spectrometry (completed by Suzhou Putai Biotechnology Co., Ltd.), and the detected peptides were compared with the theoretical sequence. The comparison results are shown in the figure. Figure 3 and 4 shown.

[0105] from Figure 3 , 4 It can be seen that the peptides detected after enzymatic hydrolysis of 705, 706, 707, 708, 709, and 710 all belong to the theoretical sequence of the corresponding collagen, indicating that each collagen was successfully expressed, and further indicating that the recombinant 705, 706,

[0106] 707, 708, 709 and 710 collagen. Figure 3 The comparison results of the characteristic peptides of 705, 706, 707, 708, 709, and 710 with the sequences of human type VII collagen α1 chain in the database and the theoretical sequence are shown. Figure 4 The red one is the theoretical sequence compared. Figure 3 The results show that the band of about 5KD contains 1-2 major proteins, matching the characteristic peptide of human type VII collagen α1 chain in the recorded peptide coverage. The relative abundance of human type VII collagen α1 chain in this band is more than 75%, confirming that it is human type VII collagen α1 chain. Trypsin is used for protein spectrum identification, and the enzyme cleavage sites are K and R. The peptides after enzyme cleavage generally end with K or R. When searching the database and analyzing the software, the peptide in the middle of KR is also the detection peptide. If the N-terminal sequence of the sequence is the middle part in the database sequence, the theoretical enzyme cleavage peptide in the software analysis has one more amino acid than the database, so it cannot be matched. Sequences 708 and 709 belong to this situation, but they can be compared with the theoretical sequence, and the relative abundance is 86.6% and 97.1%, confirming that the target protein sequence has been synthesized.

[0107] S5. High-density fermentation and purification test:

[0108] (1) The recombinant engineered bacteria selected in step 3 are subjected to a high-density fermentation test to express and produce the recombinant 705, 706, and 710 collagens on a large scale to obtain a fermentation broth containing the recombinant collagens.

[0109] Among them, seed culture medium YPG: yeast powder 10g / L, peptone 20g / L, glycerol 10g / L;

[0110] Fermentation medium: NH 4 H 2 PO 4 190.4g / L, KH 2 PO 4 10.06g / L, CaSO 4 ·2H 2 O1.18g / L, K 2 SO 4 18.2g / L, MgSO 4 7H 2O 14.9g / L, glycerol 40g / L; after the fermentation medium is sterilized at high temperature, PTM1 is added when the temperature drops to room temperature, and the pH is adjusted to 5.0 with ammonia water.

[0111] Feed medium: 50% W / V glycerol, plus 12 mL PTM1 trace elements per liter;

[0112] Induction medium: 100% methanol, 12 mL of PTM1 trace elements per liter;

[0113] PTM1: Sterilize by filtering with a 0.22 μm filter membrane and store at 4°C.

[0114] The batch culture conditions and induced expression conditions of the engineering strains are as follows: the batch fed-batch culture method is adopted, and the culture temperature is 30°C. The engineering bacteria are inoculated into a 1L shake flask containing 200ml of seed culture medium YPG, and cultured at 220rpm and 30°C for 18-20h to OD600=2~10. A 5L fermenter (Baoxing Bio) is used, with a liquid volume of 2L of fermentation medium, and 2% glycerol is sterilized separately. Before inoculation, the speed is adjusted to 300rpm, the ventilation volume is 4L / min, and the temperature is 30°C. The pH is adjusted with an alkaline solution prepared with concentrated ammonia water, and the pH is set to 4.5. Then 0.9mLPTM1 is first inoculated, and then the prepared 200ml seed liquid is inoculated into the tank (flame circle inoculation), and then the dissolved oxygen electrode is clicked to calibrate, and fermentation is started after calibration. When the dissolved oxygen drops to 30% for the first time during growth, the dissolved oxygen cascade speed function is used to maintain 30%; wait for the glycerol to be consumed, the dissolved oxygen rebounds, and the dissolved oxygen is greater than 70% (OD 600 Value is about 20), cancel the dissolved oxygen cascade speed, increase the stirring to 650rpm, use 30% linkage feeding for glycerol, and feed 80ml. Stop feeding glycerol, after the dissolved oxygen rebounds to more than 70%, set pH4 and temperature to 29℃, and use methanol and glycerol mixed carbon source (methanol: 50% glycerol = 7:3) for induction culture. Manually add 5ml, after the dissolved oxygen rebounds to more than 70%, set the feeding speed to 8ml / h, increase to 10ml / h after one hour, and increase again to 20ml / h after one hour. When the dissolved oxygen value is lower than 30%, stop feeding, wait for the dissolved oxygen to rebound, and feed linkage after the dissolved oxygen rises to 30%. After 40-60h of induction, the UV measurement of protein concentration is not obvious or decreases, and the tank can be released.

[0115] UV protein quantification formula: C (mg / mL) = 0.144*(A215-A225), A215<1.5.

[0116] The fermentation supernatant was collected and the protein electrophoresis test showed that Figure 5 As shown, under high-density fermentation conditions, each sequence collagen almost only had the target band within 24 hours of induction, and the main band proportion in optical density analysis was more than 85%.

[0117] (2) Purification:

[0118] Buffer A: 20 mM KH 2 PO4, pH 4.0;

[0119] Buffer B: 20 ​​mM KH 2 PO4, 1M NaCl, pH 4.0.

[0120] The fermentation broth in step (1) was collected, and the cells and the fermentation supernatant were separated by centrifugation at 2000g, 30min, and 4°C. The cation exchange medium was balanced with buffer A (the chromatographic filler was UniGel-80sp produced by Suzhou Nano, loaded on the XK50 / 30 chromatography column produced by Lisui Technology, and the GE AKTAPure protein separation chromatography purification system was used) until the A215 absorbance and conductivity values ​​remained unchanged, and then the flow rate of 100us / cm was set for loading, and the loading volume was 0.5L / time. The ultraviolet A215 absorbance value was detected. When it rose, the sample was started. When the A215 absorbance value dropped, the sample was stopped until the ultraviolet and conductivity dropped to the minimum and no longer changed. After the loading was completed, the sample was closed, and the cationic chromatography medium was balanced with buffer A. The eluate was collected, and after the components were detected and determined, dialyzed (the dialysate was ultrapure water), then concentrated and freeze-dried, and the freeze-dried collagen sponge was collected.

[0121] Take the purified freeze-dried sponge and dissolve it in ultrapure water, and perform protein electrophoresis. Figure 6 As shown in the figure, it can be seen that bands 705, 706 and 710 are clear and the content of the target bands is relatively high.

[0122] Example 2: Recombinant collagen cell adhesion activity experiment

[0123] In this example, natural collagen was used as a control, and recombinant 705, 706 and 710 collagens (recombinant type VII collagens with amino acid sequences as shown in SEQ ID No. 2, SEQ ID No. 4 and SEQ ID No. 12) were used as examples to examine the cell adhesion activity of the recombinant type VII collagen of the present invention.

[0124] The specific steps are as follows:

[0125] (1) Material preparation: Normally culture NIH / 3T3 cells (purchased from the Chinese Academy of Sciences Cell Bank, catalog number GNM6, culture and passaging methods refer to the cell instructions). Take recombinant 705, 706, 710 collagen freeze-dried sponges (respectively recorded as sample 1, sample 2, sample 3), and positive control human collagen (Sigma, catalog number C7774-5MG).

[0126] Among them, the processing method of positive control human collagen is as follows: weigh a 5mL sterile centrifuge tube, add human collagen in a clean bench and weigh it, subtract the weight to get the sample amount, dissolve it with ultrapure water and add acetic acid to pH 3.0 (concentration 5mg / ml), and a milky white solution can be obtained. The protein concentration is determined by the UV protein quantitative empirical formula: C (mg / mL) = 0.144*(A215-A225), and when used, it is diluted to a concentration of 0.5mg / mL with serum-free DMEM culture medium, and sterilized by filtering with a 0.22μm sterile filter.

[0127] (2) Coating preparation:

[0128] 100 μL of samples (standard / sample / blank control) were added to the 96-well plate. Standard: positive control human collagen 0.5 mg / mL (Sigma, catalog number C7774-5MG); Sample: 705, 706, 710 (representing sample 1, sample 2, sample 3, respectively) collagen 0.5 mg / mL; Blank: D-PBS phosphate buffer.

[0129] Four wells were coated with each sample and incubated at 37°C with 5% CO 2 (v / v) incubator for 1 h-4 h, remove excess coating solution from the wells, add 100 μL 1% BSA-PBS solution, and incubate at 37°C, 5% CO 2 Incubate in the incubator for 1 hour. After removing the liquid in the wells, wash three times with D-PBS and discard the washing solution. Premix Hoechst-33342 fluorescent dye (10%) with complete culture medium and dilute NIH / 3T3 cells to 5×10 4 100 μL of cells were added to the wells, covered with aluminum foil, and incubated at 37°C with 5% CO 2 Incubate for 1 hour. Measure 3 replicate samples, the fourth well is used to adjust the microscope parameters, and its measurement value is not used. The experiment shows that the sample has stronger adhesion after coating and is better than the positive control group ( Figure 7 ), which indicates that the recombinant type VII collagen of the present invention has better cell adhesion than natural collagen.

[0130] Example 3: Recombinant collagen cell migration experiment

[0131] In this example, NIH / 3T3 cells consistent with those in Example 2 were used to examine the cell migration ability of recombinant 705 (SEQ ID No. 2), 706 (SEQ ID No. 4), 710 (SEQ ID No. 12) collagen freeze-dried sponges (respectively referred to as sample 1, sample 2, and sample 3) and positive control human collagen (Sigma, catalog number C7774-5MG).

[0132] (1) Experimental preparation: First, use a marker pen to draw horizontal lines evenly on the back of a 6-well plate, using a ruler. Draw lines approximately every 0.5 cm to 1 cm across the wells, with 3 lines drawn across each well. Add approximately 5 × 10 5 cells.

[0133] (2) Scratch test: On the second day of cell culture, use the tip of the gun to measure the ruler and scratch as perpendicular to the horizontal line on the back as possible. The tip of the gun should be vertical and not tilted. Then rinse the cells with PBS three times, remove the scratched cells, and add serum-free culture medium containing the test sample as the experimental group. The concentration is 0.05% (mass volume ratio). Place at 37°C and 5% CO 2 The cells were cultured in an incubator, and samples were taken at 0, 6, and 24 hours and photographs were taken.

[0134] (3) Data processing: The scratch area of ​​each image was calculated using ImageJ image processing software, and the migration rate of each group of cells was calculated by dividing the total area of ​​the migrating cells in the fixed scratch area by the initial area of ​​the fixed scratch area. The time was used as the horizontal axis and the migration area ratio was used as the vertical axis (unit %). The photos of the experimental group and the control group at the initial time 0 and the end of the experiment were compared. The data differences of each experimental group were analyzed using a one-way ANOVA and the chi-square test. The experimental results are shown in Figure 2. Figure 8 and Fig. 9 shown.

[0135] Combination Figure 8 and Fig. 9 It can be seen that the experimental time is 24 hours. There is no significant difference between the experimental group and the blank control group at 6 hours of the experiment. The cell migration rate of the sample group is higher after 24 hours of the experiment. This shows that the cells are growing continuously over time. Under physiological conditions, the promoting effect of the experimental group samples on cell migration is more obvious, which can effectively promote the adhesion of cells to biomaterials.

[0136] In summary, the recombinant type VII collagen obtained by the method of the present invention has similar physical and chemical properties and biological functions to the original sequence, has a smaller molecular weight, and has a better effect on tissue absorption. The present invention uses NIH / 3T3 cells cultured in vitro to conduct cell adhesion experiments with type VII collagen and commercial collagen. The experiment shows that there is no significant difference in the adhesion activity of the recombinant type VII collagen of the present invention and commercial type I collagen.

[0137] The embodiments are preferred implementations of the present invention, but the present invention is not limited to the above-mentioned implementations. Any obvious improvements, substitutions or modifications that can be made by those skilled in the art without departing from the essential content of the present invention belong to the protection scope of the present invention.

Claims

1. A type VII collagen, characterized in that The type VII collagen is an amino acid sequence as shown in SEQ ID No.1, SEQ ID No.3, SEQ ID No.5, SEQ ID No.7, SEQ ID No.9 or SEQ ID No.

11.

2. A nucleic acid encoding the type VII collagen according to claim 1.

3. A recombinant vector, characterized in that: The recombinant vector comprises the nucleic acid according to claim 2.

4. The recombinant vector according to claim 3, characterized in that The recombinant vector includes pPICZαB, pFLDα, and pPIC9K, and the connection site is between XhoI and NotI.

5. The method for preparing type VII collagen according to claim 1, characterized in that: The method comprises: (1) Selecting a type VII collagen sequence to construct a collagen tandem sequence, and then constructing a recombinant expression vector comprising the collagen tandem sequence; the amino acid sequence of the collagen tandem sequence is a sequence as shown in SEQ ID No. 2, SEQ ID No. 4, SEQ ID No. 6, SEQ ID No. 8, SEQ ID No. 10 or SEQ ID No. 12; (2) The obtained recombinant expression vector was linearized with Sal I to obtain a linearized plasmid; (3) The linearized plasmid is electroporated into a host bacterium, and the recombinant engineered bacterium containing or expressing type VII collagen is screened and verified, and the expression is induced by fermentation to obtain the type VII collagen.

6. The method for preparing type VII collagen according to claim 5, characterized in that: The nucleic acid encoding the collagen tandem sequence is a nucleotide sequence as shown in SEQ ID No.13 to SEQ ID No.18 or a degenerate sequence thereof.

7. The method for preparing type VII collagen according to claim 5, characterized in that: In step (1), the recombinant expression vector includes pPICZαB, pFLDα, and pPIC9K, and the connection site is between XhoI and NotI.

8. The method for preparing type VII collagen according to claim 5, characterized in that: In step (3), the host bacteria include Pichia pastoris, Saccharomyces cerevisiae, and Hansenula.

9. The method for preparing type VII collagen according to claim 8, characterized in that: The host bacteria is Pichia pastoris.

10. The method for preparing type VII collagen according to claim 5, characterized in that: In step (3), the recombinant engineered bacteria are deposited in the General Microbiology Center of China National Microbiological Culture Collection Administration, with the deposit numbers being: CGMCC No.29601, CGMCC No.29602, CGMCC No.29603, CGMCC No.29604, CGMCC No.29605, and CGMCC No.29606.

11. A composition, characterized in that The composition comprises the type VII collagen described in claim 1, or the type VII collagen encoded by the nucleic acid described in claim 2, or the recombinant vector described in any one of claims 3 to 4; the composition is a biomaterial, a tissue engineering product, or a cosmetic.

12. A product, characterized in that The product comprises the type VII collagen described in claim 1, or the type VII collagen encoded by the nucleic acid described in claim 2, or the recombinant vector described in any one of claims 3 to 4, or the composition described in claim 11; the product is a biomaterial, a tissue engineering product, or a cosmetic.

13. Use of the type VII collagen described in claim 1, or the type VII collagen encoded by the nucleic acid described in claim 2, or the recombinant vector described in any one of claims 3 to 4, or the composition described in claim 11, or the product described in claim 12 in the preparation of biomaterials, tissue engineering products, and cosmetics that promote cell adhesion.